Follistatin-344 dosage: reported doses and schedule
Human gene-therapy findings do not establish a dose for follistatin-344 protein vials.
Also called: FS344, FST344, FS-344, Follistatin 344.
Myostatin pathway · Myostatin- and activin-binding protein precursor.
Typical reported dose: 100 mcg once a day
- Reported 100 mcg daily course: 100 mcg daily daily, under the skin. Reported by users, rare report. Studied in: Adults discussing self-use for muscle growth. (source)
- Same log, intramuscular use: 100 mcg daily after changing route daily, into muscle. Reported by users, rare report. Studied in: Adults discussing self-use for muscle growth. (source)
- Circulating daily range: 100–200 mcg daily for 10–30 days daily, under the skin. Reported by users, rare report. Studied in: Adults discussing self-use for muscle growth. (source)
- Circulating training-day schedule: 50 mcg on training days on training days only, into muscle. Reported by users, rare report. Studied in: Adults discussing self-use for muscle growth. (source)
- Whole-vial exposure in eye cases: Adverse-event exposure in a retrospective eye-clinic case series: complete 1 mg vials injected subcutaneously; not an established treatment regimen. one reported injection; repeats varied, under the skin. Reported by users, rare report. Studied in: Eleven male bodybuilding athletes presenting with central serous chorioretinopathy after self-directed injections. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Follistatin-344
- ACE-031: An experimental muscle-growth protein whose Duchenne program stopped over bleeding concerns.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- IGF-1 LR3: An unapproved growth signal with no human trials found.
- PEG-MGF: A modified MGF peptide with no human dosing studies and uncertain identity in unregulated vials.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Anaphylaxis, NHS · NHS · 2023
- Definition of the Term “Biological Product” Final Regulatory Impact Analysis, FDA · 2020
- Tailor Made Compounding LLC - 594743 - 04/01/2020, FDA · FDA · 2020
- Australian Register of Therapeutic Goods (ARTG), Therapeutic Goods Administration · TGA
- Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application Guidance for Industry, FDA
- Search criteria - Drug Product Database online query, Health Canada · Health Canada
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.